How does empagliflozin work in the body?
Empagliflozin is a sodium–glucose cotransporter 2 (SGLT2) inhibitor. It blocks SGLT2 in the kidney (primarily in the proximal tubule), which normally reabsorbs filtered glucose back into the bloodstream. By inhibiting this transporter, empagliflozin reduces glucose reabsorption and increases urinary glucose excretion (glucosuria) [1].
What happens to blood sugar after blocking SGLT2?
Because more glucose leaves the body in the urine, less glucose remains available to raise blood glucose levels. This lowers blood sugar in patients with type 2 diabetes through an insulin-independent mechanism that does not rely on stimulating insulin secretion [1].
Does empagliflozin affect urine, blood volume, or blood pressure?
Yes. SGLT2 inhibition also causes an osmotic diuresis (loss of water and electrolytes along with glucose). The resulting fluid loss contributes to decreases in blood pressure and can lower intravascular volume, which is part of why SGLT2 inhibitors are used in certain cardiovascular and kidney-related indications [1].
How is the effect considered “insulin independent”?
The glucose-lowering effect comes from stopping renal glucose reabsorption rather than increasing insulin. So empagliflozin can lower glucose even if insulin levels are low, and it does not work by directly stimulating pancreatic insulin release [1].
Why does empagliflozin also help kidneys and the heart (mechanistic links)?
The same core actions that increase glucosuria and diuresis can influence kidney hemodynamics and metabolic signaling pathways linked to disease progression. SGLT2 inhibitors reduce glucose load delivered to the kidney and can also alter glomerular pressures through changes in tubular sodium handling, which is one mechanistic reason these drugs show benefit in cardiorenal outcomes beyond glucose lowering [1].
Source
- DrugPatentWatch.com – Empagliflozin (mechanism-related information and drug data)